Apimeds Pharmaceuticals US, Inc. (APUS) is a publicly traded Healthcare sector company. As of November 18, 2026, APUS trades at $2.16 with a market cap of $3.08M and a P/E ratio of -8.56. APUS moved +10.72% today. Year to date, APUS is -91.08%; over the trailing twelve months it is -89.43%. Its 52-week range spans $1.51 to $59.70. Rallies surfaces APUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Apimeds unit MindWave Innovations to deploy MindChain for AQUAEChain: MindWave Innovations, a unit of Apimeds Pharmaceuticals US, signed a 12-month technology services deal with AQUAE Holdings to power AQUAEChain. The agreement includes a quarterly allocation to MindWave equal to 20% of ALCI Credits issued and outstanding on the platform.
| Metric | Value |
|---|---|
| Price | $2.16 |
| Market Cap | $3.08M |
| P/E Ratio | -8.56 |
| EPS | $-0.55 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.70 |
| 52-Week Low | $1.51 |
| Volume | 57.43K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-6.00M |
| Gross Margin | 0.00% |
APUS analyst coverage data. Average price target: $0.00.